Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.

Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME.

Thyroid. 2018 Oct;28(10):1301-1310. doi: 10.1089/thy.2017.0572.

PMID:
30141373
2.

Conditional survival of patients with small renal masses undergoing active surveillance.

Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF.

BJU Int. 2018 Jul 14. doi: 10.1111/bju.14486. [Epub ahead of print]

PMID:
30007044
3.

Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer.

Fang P, Musall BC, Son JB, Moreno AC, Hobbs BP, Carter BW, Fellman BM, Mawlawi O, Ma J, Lin SH.

Int J Radiat Oncol Biol Phys. 2018 Mar 2. pii: S0360-3016(18)30328-6. doi: 10.1016/j.ijrobp.2018.02.029. [Epub ahead of print]

PMID:
29685377
4.

Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes.

Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

Urology. 2018 Jun;116:114-119. doi: 10.1016/j.urology.2018.03.017. Epub 2018 Mar 22.

PMID:
29578041
5.

Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.

Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

World J Urol. 2018 Jul;36(7):1093-1101. doi: 10.1007/s00345-018-2241-7. Epub 2018 Feb 27.

PMID:
29488096
6.

Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.

Pena I, Clayman GL, Grubbs EG, Bergeron JM Jr, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME.

Head Neck. 2018 Jan;40(1):79-85. doi: 10.1002/hed.24969. Epub 2017 Oct 16.

PMID:
29044788
7.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

PMID:
28832979
8.

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.

Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR.

Mod Pathol. 2017 Jul;30(7):1032-1041. doi: 10.1038/modpathol.2017.15. Epub 2017 Mar 10.

9.

Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients.

Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA.

Genome Med. 2017 Feb 28;9(1):21. doi: 10.1186/s13073-017-0409-1.

10.

Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Bruegl AS, Ring KL, Daniels M, Fellman BM, Urbauer DL, Broaddus RR.

Cancer Prev Res (Phila). 2017 Feb;10(2):108-115. doi: 10.1158/1940-6207.CAPR-16-0219. Epub 2016 Dec 13.

11.

Patient knowledge and information-seeking about personalized cancer therapy.

Rogith D, Yusuf RA, Hovick SR, Fellman BM, Peterson SK, Burton-Chase AM, Li Y, Bernstam EV, Meric-Bernstam F.

Int J Med Inform. 2016 Apr;88:52-7. doi: 10.1016/j.ijmedinf.2016.01.005. Epub 2016 Jan 18.

12.

Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre.

Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA.

BJU Int. 2016 May;117(5):775-82. doi: 10.1111/bju.13194. Epub 2015 Jul 5.

13.

Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.

Karam JA, Devine CE, Fellman BM, Urbauer DL, Abel EJ, Allaf ME, Bex A, Lane BR, Thompson RH, Wood CG.

BJU Int. 2016 Apr;117(4):629-35. doi: 10.1111/bju.13188. Epub 2015 Jun 29.

14.

Attitudes toward molecular testing for personalized cancer therapy.

Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, Li Y, McKinney C, Bernstam EV, Meric-Bernstam F.

Cancer. 2015 Jan 15;121(2):243-50. doi: 10.1002/cncr.28966. Epub 2014 Sep 10.

15.

Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.

Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, Luthra R, Fellman BM, Lu KH, Broaddus RR.

Gynecol Oncol. 2014 Aug;134(2):319-25. doi: 10.1016/j.ygyno.2014.06.009. Epub 2014 Jun 14.

16.

Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction.

Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P.

J Natl Compr Canc Netw. 2013 Nov;11(11):1389-97.

17.

Randomized controlled trial of a sun protection intervention for children of melanoma survivors.

Gritz ER, Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Urbauer DL, Fellman BM, Lee JE, Gershenwald JE.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1813-24. doi: 10.1158/1055-9965.EPI-13-0249.

Supplemental Content

Loading ...
Support Center